uniQure (NASDAQ:QURE) CEO Sells $285,978.90 in Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 26,727 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $285,978.90. Following the completion of the sale, the chief executive officer now owns 571,188 shares in the company, valued at $6,111,711.60. This represents a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

uniQure Stock Up 8.9 %

QURE stock opened at $13.15 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock has a market capitalization of $640.73 million, a P/E ratio of -2.65 and a beta of 0.38. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The business has a 50-day moving average of $15.05 and a 200-day moving average of $9.81.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on QURE shares. The Goldman Sachs Group increased their target price on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. StockNews.com raised uniQure to a “sell” rating in a research note on Wednesday, February 5th. Wells Fargo & Company decreased their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday. Mizuho raised their price target on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. Finally, Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

Hedge Funds Weigh In On uniQure

A number of large investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC acquired a new stake in shares of uniQure in the fourth quarter valued at approximately $38,410,000. Franklin Resources Inc. grew its position in uniQure by 33.1% in the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company’s stock valued at $35,103,000 after purchasing an additional 494,726 shares in the last quarter. abrdn plc increased its stake in uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after buying an additional 1,528,581 shares during the last quarter. Point72 Asset Management L.P. lifted its position in uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock worth $31,282,000 after buying an additional 794,459 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its stake in shares of uniQure by 175.0% during the 4th quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $19,426,000 after buying an additional 700,000 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.